Clinical Trial Update: Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study [Phase 3]

View source ↗

Summary

Phase 3 trial assessing Glecaprevir/Pibrentasvir with Sofosbuvir and Ribavirin in Hepatitis C patients who previously failed AbbVie studies; results posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Glecaprevir/pibrentasvir (glecaprevir/pibrentasvir)
• Ribavirin (ribavirin)
• Sofosbuvir (sofosbuvir)

Snippet

Sponsor: AbbVie | Conditions: Hepatitis C Virus Infection | Phase 3 | Status: COMPLETED | Results posted: 2022-05-04